Patents Examined by Samuel Liu
  • Protein refolding column filler and column
    Patent number: 8394933
    Abstract: It is an object of the present invention to provide: a protein refolding column filler, which is effective for the refolding, namely, the activation of the function, of an inactive protein with an as yet unformed higher order structure produced in Escherichia coli or the like, or a protein whose conformation has been changed due to a certain cause and which has become inactivated; and a column filled with the aforementioned column filler. The present invention provides a protein refolding column filler, which comprises zeolite with BEA structure (Zeolite Beta) that is granulated into a particle state.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: March 12, 2013
    Assignee: FUJIFILM Corporation
    Inventors: Masayuki Kawakami, Tatsuo Tsunoda, Hideaki Togashi, Takayuki Nara, Shun-ichi Matsuura, Chisato Sekikawa, Akiko Kawai, Akiyoshi Kawata, Fujio Mizukami, Kengo Sakaguchi
  • Approach to the treatment of compartment syndrome
    Patent number: 8389468
    Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: March 5, 2013
    Assignee: Lantmannen AS-Faktor AB
    Inventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergström
  • Method of preventing adverse effects by GLP-1
    Patent number: 8377869
    Abstract: A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: February 19, 2013
    Assignee: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Donald Costello
  • Composition for treating retinopathy or glaucoma comprising thrombin derived peptides
    Patent number: 8372811
    Abstract: Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: February 12, 2013
    Assignee: Eyegene, Inc.
    Inventors: Jin Wook Jang, Hyeong Joon Lim, Yang Je Cho, Won Il Yoo, Doo Sik Kim, Oh Woong Kwon, Kyoung Chul Ko, Kyung Sul Kim
  • Delivery of active agents
    Patent number: 8372804
    Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: February 12, 2013
    Assignee: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
  • Method to produce fibrin monomer in acid media for use as tissue sealant
    Patent number: 8367802
    Abstract: A hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, it produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The fibrin components are produced by a novel dialysis method which does not present thrombin to the immune system and can be maintained in solution for six weeks without significant proteolytic degradation.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: February 5, 2013
    Assignee: Biomedica Management Corporation
    Inventors: George David Falus, Leonid Medved
  • Methods for stepwise deposition of silk fibroin coatings
    Patent number: 8354501
    Abstract: The invention provides a method for the controlled assembly of layered silk fibroin coatings using aqueous silk fibroin material. The methods described herein can be used to coat substrates of any material, shape, or size. Importantly, the described methods enable control of the biomaterial surface chemistry, thickness, morphology and structure using layered thin film coatings, or bulk coatings. Furthermore, the methods can be performed in all water and do not require intensive chemical processing enabling controlled entrapment of labile molecules such as, drugs, cytokines, and even cells or viruses to generate functional coatings that can be used in a variety of applications.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: January 15, 2013
    Assignee: Trustees of Tufts College
    Inventors: David L. Kaplan, Xianyan Wang
  • Method for extracting hydrophobin from a solution
    Patent number: 8354503
    Abstract: Process for extracting hydrophobin from a solution wherein carrageenan is added to the solution and the pH of the solution is brought below 3.5, and the ionic strength of the solution is below 0.5.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: January 15, 2013
    Assignee: Conopco, Inc.
    Inventor: Nicholas David Hedges
  • Fluorescent protein molecules
    Patent number: 8338580
    Abstract: The present invention relates to novel fluorescent proteins and to methods of making these proteins and the uses thereof.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: December 25, 2012
    Inventors: Xiaolian Gao, Jinchun Wang
  • Methods for producing soluble membrane-spanning proteins
    Patent number: 8323902
    Abstract: Methods for producing membrane-spanning polypeptides in high yields, with native conformation, and/or in soluble form include solubilizing in non-ionic or zwitterionic detergents, as well as use of promoters and expression vectors for expressing high yields of membrane-spanning polypeptides in bacterial cells. Mutated promoters provide tight control of membrane-spanning polypeptides in bacterial cell hosts.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: December 4, 2012
    Assignee: Genentech, Inc.
    Inventors: James A. Ernst, Daniel Yansura, Hok Seon Kim
  • Approach to the treatment of compartment syndrome
    Patent number: 8309513
    Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: November 13, 2012
    Assignee: Lantmannen As-Faktor AB
    Inventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergström
  • Photoreactive regulator of protein function and methods of use thereof
    Patent number: 8309350
    Abstract: The present invention provides a synthetic regulator of protein function, which regulator is a light-sensitive regulator. The present invention further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present invention further provides methods of modulating protein function, involving use of light. The present invention further provides methods of identifying agents that modulate protein function.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: November 13, 2012
    Assignee: The Regents of the University of California
    Inventors: Ehud Y. Isacoff, Richard H. Kramer, Dirk Trauner, Matthew R. Banghart, Matthew Volgraf, Pablo Ignacio Gorostiza Langa, Katharine Borges
  • Biopolymeric membrane for wound protection and repair
    Patent number: 8298584
    Abstract: The present invention relates to a conformable and semi-permeable biopolymeric membrane suitable for tissue repair and protection. This membrane contains a first layer made from randomly oriented, reconstituted biopolymer fibers and, on top of the first layer, a coating layer made from biopolymer fibers.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: October 30, 2012
    Assignee: Collagen Matrix, Inc.
    Inventors: Shu-Tung Li, Natsuyo Shishido Lee, Debbie Yuen
  • Self-assembling peptide and gel produced from the same
    Patent number: 8299032
    Abstract: A self-assembling peptide containing a polar amino acid residue and a nonpolar amino acid residue, wherein the self-assembling peptide contains an acidic amino acid residue and a basic amino acid residue as the polar amino acid residues, a total sum of charge of the acidic amino acid residue and charge of the basic amino acid residue in a neutral region is the number excluding 0, and the self-assembling peptide is capable of forming a beta (?)-sheet structure in which only the nonpolar amino acid residue is arranged on one face upon self-assembly in an aqueous solution.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: October 30, 2012
    Assignee: Menicon Co., Ltd.
    Inventors: Hidenori Yokoi, Takatoshi Kinoshita
  • Exendin and exendin agonists for eating disorders
    Patent number: 8288338
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: October 16, 2012
    Assignee: Amylin Pharmaceuticals, LLC
    Inventors: Andrew A. Young, Sunil Bhavsar, Bronislava Gedulin
  • Preparation of annexin derivatives
    Patent number: 8283167
    Abstract: Labeled annexin is formed by reacting annexin or a modified annexin with a phosphatidylserine group or an analogue of phosphatidylserine. This phosphatidylserine annexin conjugate is then reacted with an appropriate label to form a labeled annexin and the annexin is separated from the phosphatidylserine group. The reaction between the phosphatidylserine group and the annexin is calcium ion concentration dependent. Therefore, the reaction can be promoted by having a high calcium ion concentration and the separation of the phosphatidyl group from the annexin group is facilitated by reducing the calcium ion concentration preferably by addition of an appropriate calcium chelating agent.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: October 9, 2012
    Assignee: Clear Vascular Inc.
    Inventor: Jaime Simon
  • Directed evolution of GRG31 EPSP synthase enzyme
    Patent number: 8247535
    Abstract: Compositions and methods for conferring herbicide resistance or tolerance to bacteria, plants, plant cells, tissues and seeds are provided. Compositions include polynucleotides encoding herbicide resistance or tolerance polypeptides, vectors comprising those polynucleotides, and host cells comprising the vectors. The nucleotide sequences of the invention can be used in DNA constructs or expression cassettes for transformation and expression in organisms, including microorganisms and plants. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated polynucleotides encoding glyphosate resistance or tolerance polypeptides are provided, particularly polypeptide variants of SEQ ID NO:2 and 4. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: August 21, 2012
    Assignee: Athenix Corp.
    Inventors: Volker Heinrichs, Laura Cooper Schouten, Brian Vande Berg
  • Method of secretory expression of lysostaphin in at high level
    Patent number: 8241901
    Abstract: A method of secretory expression of lysostaphin in Escherichia coli at high level, which comprises constructing a expression vector by cloning a sequence encoding a signal peptide which is suitable for secretory expression in Escherichia coli before part or whole gene sequence which encodes mature lysostaphin, and ligating the cloned sequence with a promoter; and transforming Escherichia coli with the expression vector, culturing and fermenting, and then isolating lysostaphin from the supernatant of the fermentation broth. The advantage of secretory expression is that the expression product can exist in the medium in an active form, and thus does not need the process for renaturation of the inclusion body; it is more easily to purify from the supernatant of the fermentation broth with high rate of recovery; and there is less contamination from the host's proteins.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: August 14, 2012
    Assignee: Shanghai Hi-Tech United Bio-Technological Research & Development Co., Ltd.
    Inventors: Qingshan Huang, Hairong Lu, Wanying Lu
  • Methods for producing modified glycoproteins
    Patent number: 8211691
    Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: July 3, 2012
    Assignee: Glycofi, Inc.
    Inventor: Tillman U. Gerngross
  • Photoreactive regulator of glutamate receptor function and methods of use thereof
    Patent number: 8178496
    Abstract: The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: May 15, 2012
    Assignee: The Regents of the University of California
    Inventors: Dirk Trauner, Ehud Y. Isacoff, Matthew Volgraf, Pablo Ignacio Gorostiza Langa